Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,098,867
  • Shares Outstanding, K 135,814
  • Annual Sales, $ 48,660 K
  • Annual Income, $ -290,580 K
  • 60-Month Beta 1.46
  • Price/Sales 80.47
  • Price/Cash Flow N/A
  • Price/Book 4.83
Trade DNLI with:

Options Overview Details

View History
  • Implied Volatility 76.73% ( -6.71%)
  • Historical Volatility 78.21%
  • IV Percentile 38%
  • IV Rank 66.71%
  • IV High 92.24% on 09/23/22
  • IV Low 45.65% on 12/07/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 21
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,961
  • Open Int (30-Day) 1,945

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.82
  • Number of Estimates 8
  • High Estimate -0.61
  • Low Estimate -0.98
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -32.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.52 +13.80%
on 11/04/22
32.72 -7.76%
on 11/11/22
+0.56 (+1.89%)
since 10/28/22
3-Month
25.88 +16.62%
on 09/26/22
34.78 -13.23%
on 10/18/22
+1.48 (+5.16%)
since 08/29/22
52-Week
20.24 +49.11%
on 05/12/22
48.46 -37.72%
on 12/23/21
-14.84 (-32.96%)
since 11/26/21

Most Recent Stories

More News
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus

Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.

SNY : 44.50 (-2.99%)
BIIB : 301.00 (+3.29%)
DNLI : 30.18 (+4.68%)
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 30.18 (+4.68%)
TNGX : 7.22 (+2.85%)
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

DNLI : 30.18 (+4.68%)
TAK : 14.50 (-0.34%)
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.

BMRN : 97.12 (-1.56%)
INCY : 77.80 (-0.04%)
ITCI : 52.85 (+1.32%)
DNLI : 30.18 (+4.68%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 30.18 (+4.68%)
EVLO : 1.9400 (-2.51%)
FHTX : 6.73 (-6.66%)
MRNA : 173.95 (+0.46%)
OMGA : 6.71 (+0.15%)
RUBY : 0.2017 (-2.61%)
SANA : 4.71 (+1.07%)
MCRB : 6.70 (+0.75%)
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

DNLI : 30.18 (+4.68%)
ZYME : 7.71 (-1.53%)
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DNLI : 30.18 (+4.68%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 30.18 (+4.68%)
EVLO : 1.9400 (-2.51%)
FHTX : 6.73 (-6.66%)
MRNA : 173.95 (+0.46%)
OMGA : 6.71 (+0.15%)
RUBY : 0.2017 (-2.61%)
SANA : 4.71 (+1.07%)
MCRB : 6.70 (+0.75%)
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus

Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.

SNY : 44.50 (-2.99%)
BIIB : 301.00 (+3.29%)
DNLI : 30.18 (+4.68%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DNLI : 30.18 (+4.68%)
CDTX : 0.6770 (-4.65%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 32.43
2nd Resistance Point 31.45
1st Resistance Point 30.81
Last Price 30.18
1st Support Level 29.19
2nd Support Level 28.21
3rd Support Level 27.57

See More

52-Week High 48.46
Fibonacci 61.8% 37.68
Fibonacci 50% 34.35
Fibonacci 38.2% 31.02
Last Price 30.18
52-Week Low 20.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar